Lilly Withdraws Application For Additional U.S. Indication For ... - Medical News Today
Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (R) (duloxetine HCl) for the management of...